Sunscreen Bill Would Expedite TEA Decisions, Set Deadlines
This article was originally published in The Rose Sheet
The Sunscreen Innovation Act, introduced in both the House and the Senate, would streamline the process for FDA review of sunscreen TEAs and impose deadlines for agency action.
You may also be interested in...
The House Energy and Commerce Health subcommittee unanimously advanced the Sunscreen Innovation Act to full committee June 19, but provisions in the original bill seeking a tight timeline for FDA’s review of sunscreen ingredient time-and-extent applications are now in limbo, according to the Public Access to Sunscreens coalition of stakeholders.
While the Environmental Working Group supports the Sunscreen Innovation Act, it would like to see realistic deadlines put in place to accelerate FDA’s review of sunscreen-ingredient time-and-extent applications without including a default mechanism that would grant free market access to certain sunscreen actives when FDA fails to act within allotted timeframes.
Legislators and stakeholders are optimistic that the Sunscreen Innovation Act, which calls for an acceleration of FDA’s review of sunscreen active-ingredient time-and-extent applications, will pass this year. The House version of the bill is expected to advance first.